For how we live.
A $12 million gift will test whether low-dose rapamycin changes the transition to frailty in adults over 65 — the first study of the drug designed around an outcome rather than a biomarker.
The longest human trial of low-dose rapamycin for healthy ageing found no change in visceral fat, its own primary outcome. The positive findings it is quoted for rest on eight women.
A ten-person phase 1 study measured whether oral rapamycin reaches the central nervous system in early Alzheimer's. It did not — and several disease biomarkers rose over eight weeks.
A 2025 review walked through every study of low-dose rapamycin in healthy adults. The immune findings are real, the outcome data do not exist, and the review's own worked example does not add up.
Two real-world cohorts found lower blood levels per milligram from compounded formulations — and the longest longevity trial of rapamycin was run on the weaker one, which changes how to read it.